

Persistent Systems

Estimate change	↑
TP change	↑
Rating change	↔

Bloomberg	PSYS IN
Equity Shares (m)	156
M.Cap.(INRb)/(USD b)	834.8 / 9.4
52-Week Range (INR)	6789 / 4149
1, 6, 12 Rel. Per (%)	-1/7/-5
12M Avg Val (INR M)	3142

Financials & Valuations (INR b)

Y/E Mar	FY26E	FY27E	FY28E
Sales	146.1	175.9	209.7
EBIT Margin (%)	15.7	16.2	16.0
Adj. PAT	18.6	23.0	27.0
Adj. EPS (INR)	119.1	147.0	172.7
EPS Gr.(%)	32.0	23.4	17.5
BV/Sh.(INR)	478.5	566.7	670.9

Ratios

RoE (%)	27.1	28.3	28.1
RoCE (%)	24.5	25.7	25.5
Payout (%)	40.0	40.0	40.0

Valuations

P/E (x)	44.8	36.3	30.9
P/BV (x)	11.2	9.4	8.0
EV/EBITDA (x)	29.9	24.4	20.5
Div. Yield (%)	0.9	1.1	1.3

Shareholding pattern (%)

As On	Jun-25	Mar-25	Jun-24
Promoter	30.6	30.7	31.0
DII	27.8	26.9	28.2
FII	24.8	25.2	23.2
Others	16.9	17.3	17.5

FII Includes depository receipts

CMP: INR5,338 TP: INR6,550 (+23%) Buy

In the pink of health

Healthy beat justifies premium valuations

- Persistent Systems (PSYS) reported 2QFY26 revenue of USD406m (vs. est. USD404m), up 4.2% QoQ in USD terms and 4.4% in CC (est. +3.5%). EBIT margin stood at 16.3% (est. 15.7%).
- EBIT grew 12.7% QoQ/43.7% YoY to INR5.8b. Adj. PAT came in at INR4.7b (est. INR4.4b), up 11% QoQ/45% YoY. For 1HFY26, revenue/EBIT/PAT grew 22.7%/39.4%/42.0% YoY in INR terms.
- We expect revenue/EBIT/PAT to grow 22.1%/24.7%/25.5% YoY in 2HFY25. TTM TCV was USD609m, up 17% QoQ/15% YoY (1.5x book-to-bill). Given its consistent execution and visibility on growth, we value PSYS at 43x Jun'27E EPS. Reiterate **BUY** with a TP of INR6,550.

Our view: Deal TCV improving even as demand remains uncertain

- **Growth came in above estimates; FY27 target intact:** PSYS reported 4.4% QoQ CC growth in 2QFY26, coming in ahead of estimates, driven by traction in BFSI (+7.0% QoQ) and steady growth in Healthcare (+3.8% QoQ). At a CQGR of around 4.5% over the next couple of quarters, PSYS should comfortably deliver ~17.5% YoY CC growth in FY26E. While this is a slight moderation from FY25 levels, it remains healthy in the current demand environment. The company also reaffirmed its USD2b revenue target by FY27, implying ~18% CC CAGR over FY25-27.
- **Margin performance admirable:** EBIT margin stood at 16.3%, up 80bp QoQ. The improvement was supported by a few one-offs and operational levers: +80bps from software license cost reversal for one client, +60bps from currency gain, and +30bps from offshoring ramp-up for a large healthcare client, partly offset by -50bps from higher doubtful debt provisions, -20bps from lower utilization, and -20bps from IT amortization and depreciation.
- We do expect some margin pullback in 3Q due to wage hikes. Utilization stands at 87% and key margin levers are now peaked out. SG&A leverage continues to be a key margin lever. Currency gains have been a broad positive this quarter; however, if the currency moves unfavorably, it could turn into a near-term risk. We factor in margin expansion of 100bps over FY26E (and another 50bps by FY27E), even as management guides for around 100bps improvement in FY27.
- **Pipeline remains healthy, but conversion remains key:** TTM TCV stood at USD609m, up 15% YoY, with a healthy 1.5x book-to-bill ratio. That said, net new deal TCV remains a bit soft. Conversion will remain the key monitorable in the near term. PSYS continues to chase larger deals and sharpen its focus on TCV-to-ACV conversion, supported by good traction in BFSI and growing adoption of AI-led programs.

Valuation and revisions to our estimates

- **We project a 19% USD revenue CAGR over FY25-27 for PSYS**, which, combined with margin expansion, could result in ~26% EPS CAGR. This places the company in a league of its own as a diversified product engineering and IT services player.
- We revise our FY27E estimates upward by 4%, reflecting continued revenue momentum and steady margin gains. We factor in margin expansion of 100bps over FY26E (and another 50bps by FY27E), while our FY25/FY26 estimates remain largely unchanged. Owing to its superior earnings growth trajectory, on a PEG basis, we believe the valuation still has room for upside. We value PSYS at 43x Jun'27E EPS. **Reiterate BUY with a TP of INR6,550.**

Beat on revenue and margins; deal TCV momentum returns

- 2QFY26 revenue stood at USD 406m, up 4.2% QoQ in USD terms (above our estimate of 3.7% QoQ). The company reported CC growth of 4.4% QoQ vs our estimate of 3.5% QoQ CC growth.
- Growth was led by BFSI (up 7.0% QoQ) and Healthcare (up 3.8% QoQ).
- EBIT margin at 16.3% was up 80bps QoQ and above our estimate of 15.7%.
- TCV was USD609m, up 17% QoQ/15% YoY (1.5x book-to-bill).
- Net new TCV was up 4% QoQ at USD350.8m. ACV stood at USD447m.
- Net headcount improved by 3.5% QoQ. Utilization dipped 50bp QoQ at 88.2%. TTM attrition was down 10bp QoQ at 13.8%.
- EBITDA grew 11.8% QoQ/42% YoY to INR6.8b. EBITDA margin came in at 19.1%, above our estimate of 18.4%.
- Adj. PAT stood at INR4.7b (up 11% QoQ/45% YoY), above our estimate of INR4.4b.

Key highlights from the management commentary

- The macro environment remains mixed; however, it is gradually stabilizing as stakeholders adapt to it. It remains confident in its ability to sustain a historical growth momentum.
- The industry is expected to continue reporting robust deal wins going forward.
- The company remains committed to strengthening its capabilities in AI.
- BFSI is expected to lead growth due to deal ramp-ups and a healthy pipeline, followed by Hi-Tech and Healthcare.
- It is still early for AI to have a significant impact on renewal deal revenues; however, the company is proactively integrating AI-led solutions with its top 100 customers (~82% of revenue).
- Offshoring ratio remains optimal at ~85%. The pricing structure is aligned with customer agreements to ensure a fair realization.
- Wage hikes effective from 1st Oct 2025 for all employees are expected to impact margins by 180bps in 3Q; however, ~80-100bp of this impact is expected to be offset through utilization, offshoring, and subcontractor rationalization.
- Healthcare & Life Sciences (HLS): Large deals are progressing through ramp-up, offshoring, and optimization cycles.
- SASVA streamlines SDLC and optimizes GPU infrastructure for scale. The company has filed 20 new patents, bringing the total SASVA patents to 75.

Valuation and view

- **We project a 19% USD revenue CAGR over FY25-27 for PSYS**, which, combined with margin expansion, could result in a ~26% EPS CAGR. This places the company in a league of its own as a diversified product engineering and IT services player.
- We revise our FY27E estimates upward by 4%, reflecting continued revenue momentum and steady margin gains. We factor in margin expansion of 100bps over FY26E (and another 50bps by FY27E), while our FY25/FY26 estimates remain largely unchanged. Owing to its superior earnings growth trajectory, on a PEG basis, we believe the valuation still has room for upside. We value PSYS at 43x Jun'27E EPS. **Reiterate BUY with a TP of INR6,550.**

Quarterly Performance (IFRS)

Y/E March (Consolidated)	FY25				FY26E				FY25	FY26E	Est. 2QFY26	Var. (% / bp)
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE				
Revenue (USD m)	328	346	360	375	390	406	424	443	1,409	1,664	404.0	0.5
QoQ (%)	5.6	5.3	4.3	4.2	3.9	4.2	4.5	4.5	18.8	18.1	3.7	57bp
Revenue (INR m)	27,372	28,972	30,623	32,421	33,336	35,807	37,641	39,334	1,19,387	1,46,118	35,259	1.6
QoQ (%)	5.7	5.8	5.7	5.9	2.8	7.4	5.1	4.5			5.8	164bp
YoY (%)	17.9	20.1	22.6	25.2	21.8	23.6	22.9	21.3	21.6	22.4	21.7	189bp
GPM (%)	33.0	33.4	34.7	34.9	35.3	36.0	34.0	36.0	34.0	35.3	35.0	98bp
SGA (%)	16.4	16.8	17.1	16.8	16.9	16.9	16.6	17.0	16.8	16.9	16.6	28bp
EBITDA	4,552	4,807	5,378	5,844	6,116	6,838	6,549	7,474	20,581	26,977	6,488	5.4
EBITDA Margin (%)	16.6	16.6	17.6	18.0	18.3	19.1	17.4	19.0	17.2	18.5	18.4	70bp
EBIT	3,840	4,062	4,557	5,053	5,178	5,837	5,571	6,411	17,512	22,998	5,536	5.5
EBIT Margin (%)	14.0	14.0	14.9	15.6	15.5	16.3	14.8	16.3	14.7	15.7	15.7	60bp
Other income	165	283	263	-1	376	331	301	315	710	1,323	282	17.3
ETR (%)	23.5	25.2	22.6	21.7	23.5	23.6	23.3	23.5	23.2	23.5	23.0	
Adj. PAT	3,064	3,250	3,729	3,958	4,249	4,715	4,504	5,146	14,001	18,613	4,480	5.2
QoQ (%)	-2.8	6.1	14.7	6.1	7.4	10.9	-4.5	14.2			5.4	553bp
YoY (%)	10.5	23.4	30.3	25.5	38.7	45.1	20.8	30.0	22.6	32.9	37.8	723bp
Reported EPS (INR)	19.9	21.0	23.9	25.4	27.2	30.2	28.8	32.9	90.2	119.1	28.7	5.1

Key Performance Indicators

Y/E March	FY25				FY26		FY25
	1Q	2Q	3Q	4Q	1Q	2Q	
Revenue (QoQ CC %)	5.6	5.1	4.6	4.5	3.3	4.4	
Margins							
Gross Margin	33.0	33.4	34.7	34.9	35.3	36.0	34.0
EBIT Margin	14.0	14.0	14.9	15.6	15.5	16.3	14.7
Net Margin	11.2	11.2	12.2	12.2	12.7	13.2	11.7
Operating metrics							
Headcount	23,519	23,237	23,942	24,594	25,340	26,224	24,594
Voluntary Attrition (%)	11.9	12.0	12.6	12.9	13.9	13.8	12.9
Utilisation (%)	82.1	84.8	87.4	88.4	88.7	88.2	88.4
Effort Mix(%)							
Global Delivery Centers	15.2	15.8	15.1	14.8	14.5	14.1	15.2
India	84.8	84.2	84.9	85.2	85.5	85.9	84.8



Highlights from the management commentary

Growth and demand outlook

- Macro remains mixed, but the environment is stabilizing as stakeholders adapt to it. The company is confident of sustaining historical growth momentum.
- The industry is expected to continue reporting good deal wins going forward.
- The company remains committed to strengthening capabilities in AI. It is making steady progress toward achieving USD2b revenue by the end of FY27. The tech services industry is evolving toward “Service-as-Software” end-to-end solutions, combining services, software, and outcomes.
- 2QFY26 revenue stood at USD406m, up 4.2% QoQ in USD terms (+4.4% in CC).
- The company has reported robust growth across all client cohorts. BFSI is expected to lead growth due to deal ramp-ups and a healthy pipeline, followed by Hi-Tech and Healthcare.
- It is still early for AI to have a significant impact renewal deal revenues; however, the company is proactively integrating AI-led solutions into its top 100 customers (~82% of revenue).
- The company has maintained consistency in the TCV-to-ACV conversion. SASVA licensing revenue occasionally forms a part of large deals. AI-led deal wins are enabling the company to improve realization and margins.
- TCV stood at USD609m, up 17% QoQ / 15% YoY (book-to-bill ratio at 1.5x). Of this, USD351m came from new business.
- Growth outlook remains strong with broad-based bookings. The company has been selected by a leading cloud infra provider to build and scale AI infrastructure platforms using SASVA.
- **BFSI** led growth during the quarter. The company has been selected by a major American bank for tech debt remediation and CX transformation. Previously, it won a large multi-year deal with the same bank against a Tier-1 incumbent. Growth is broad-based across banks, fintechs, and other financial service providers.
- **Healthcare & Life Sciences (HLS):** Large deals are progressing through ramp-up, offshoring, and optimization cycles. The company faces no concerns with large clients, and its strong pipeline remains intact. It has been impacted by the “Big Beautiful Bill” in the US; it is closely supporting clients with compliance and tech solutions.
- Sub-verticalization within healthcare is yielding strong customer response and pipeline traction.
- **Europe:** Growth is driven by Hi-Tech customers, aided by the ramp-up of a previously won large deal. **North America / RoW:** No major updates have been shared.
- The company anticipates structural industry changes due to H1B visa-related developments. It may invest in onshore centers to strengthen delivery presence.
- “AI for Technology” is driving engineering hyper-productivity; “AI for Business” is focused on domain-based productivity. Enterprise data readiness framework enables secure data foundations; iAURA accelerates modernization of legacy systems.
- SASVA streamlines SDLC and optimizes GPU infrastructure for scale. The company has filed 20 new patents, bringing the total SASVA patents to 75. It

has announced new partnerships with Anthropic and DigitalOcean. Moreover, it has deployed 50+ AI agents across internal functions such as Finance, HR, and Business Delivery.

- The company is building AI capabilities faster than peers and executing them strongly on GTM. It has appointed Jaideep Dhok as the Chief Operating Officer.

Margin performance and outlook

- EBIT margin stood at 16.3%, up 80bps QoQ.
- Margin walk: +80bps from software license cost reversal for one client, +60bps from currency gain, +30bps from offshoring ramp-up for a large healthcare client; -50bps from higher doubtful debt provisions, -20bps from lower utilization, and -20bps from IT amortization and depreciation.
- Offshoring ratio remains optimal at ~85%. Its pricing structure is aligned with customer agreements to ensure fair realization.
- Wage hikes effective from 1st Oct 2025 for all employees are expected to impact margins by 180bps in 3Q; ~80-100bps of this will be offset by utilization, offshoring, and subcontractor rationalization.
- The company is comfortable with its current utilization levels and expects to maintain it for a few quarters before normalizing to 83–85%.
- Margin aspiration: +100bps improvement YoY in FY26 and FY27 each, after which growth will be prioritized.
- ETR for 2Q stood at 23.5%; FY26 guidance remains at 22.5–23.5%..

Exhibit 1: BFSI and Healthcare led growth

Verticals (QoQ USD, %)	2Q23	3Q23	4Q23	1Q24	2Q24	3Q24	4Q24	1Q25	2Q25	3Q25	4Q25	1Q26	2Q26
BFSI	3.0	2.8	2.9	6.2	0.0	-0.5	1.8	5.9	7.7	4.9	6.1	9.0	7.0
Healthcare and Lifesciences	4.8	2.9	4.4	-2.7	7.0	16.4	14.8	16.5	9.6	4.3	0.4	-1.9	3.8
Software and Hi-tech and Emerging verticals	8.3	4.1	4.3	3.2	3.8	0.1	-0.8	-0.5	0.8	3.7	5.2	3.6	2.2

Source: Company, MOFSL

Exhibit 2: Europe runs the growth show

Geographies (QoQ USD, %)	2Q23	3Q23	4Q23	1Q24	2Q24	3Q24	4Q24	1Q25	2Q25	3Q25	4Q25	1Q26	2Q26
North America	6.1	1.5	4.9	4.7	3.1	3.7	3.9	6.4	6.1	3.2	4.2	3.0	4.2
Europe	3.3	12.2	18.9	-3.0	1.0	-3.5	-9.4	5.6	6.6	8.2	6.7	11.3	7.7
RoW	5.0	10.6	-11.8	-3.1	5.0	4.0	9.8	0.3	-1.1	9.1	2.3	4.8	1.4

Source: Company, MOFSL

Valuation and view

- **We project a 19% USD revenue CAGR over FY25-27 for PSYS**, which, combined with margin expansion, could result in a ~26% EPS CAGR. This places the company in a league of its own as a diversified product engineering and IT services player.
- We revise our FY27E estimates upward by 4%, reflecting continued revenue momentum and steady margin gains. We factor in margin expansion of 100bps over FY26E (and another 50bps by FY27E), while our FY25/FY26 estimates remain largely unchanged. Owing to its superior earnings growth trajectory, on a PEG basis, we believe the valuation still has room for upside. We value PSYS at 43x Jun'27E EPS. **Reiterate BUY with a TP of INR6,550.**


Exhibit 3: Changes to our estimates

	Revised			Earlier			Change		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
INR/USD	87.5	88.7	88.7	87.6	88.7	88.7	-0.1%	0.0%	0.0%
USD Revenue (m)	1,664	1,982	2,364	1,650	1,955.3	2,309.7	0.8%	1.4%	2.3%
Growth (%)	18.1	19.2	19.3	17.1	18.5	18.1	90bps	70bps	110bps
EBIT margin (%)	15.7	16.2	16.0	15.4	15.7	16.2	30bps	50bps	-20bps
PAT (INR m)	18,613	22,982	27,007	18,078	22,006.4	26,702.1	3.0%	4.4%	1.1%
EPS	119.1	147.0	172.7	115.8	140.9	171.0	2.9%	4.3%	1.0%

Source: MOFSL, Company


Story in charts

Exhibit 4: BTB rose to 1.5x; TCV stood at USD 609m




Source: Company, MOFSL

Exhibit 5: Reported 4.4% QoQ CC growth, above estimates




Source: Company, MOFSL

Exhibit 6: Margins expanded 70bp QoQ




Source: Company, MOFSL

Exhibit 7: Utilization dipped 50bp to 88.2% in 2QFY26



Source: Company, MOFSL

Exhibit 8: Attrition rate remained flat QoQ



Source: Company, MOFSL

Exhibit 9: Operating metrics

	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26
Geography (%)									
North America	79.2	79.7	80.1	80.7	81.3	80.5	80.5	79.8	79.8
Europe	9.5	8.9	7.8	7.8	7.9	8.2	8.4	9	9.3
RoW	11.3	11.4	12.1	11.5	10.8	11.3	11.1	11.2	10.9
Vertical Mix (%)									
BFSI	32.3	31.2	30.7	30.8	31.5	31.7	32.3	33.9	34.8
Healthcare & Life Science	19.3	21.8	24.2	26.7	27.8	27.8	26.8	25.3	25.2
Tech. Cos. & Emerging Verticals	48.4	47	45.1	42.5	40.7	40.5	40.9	40.8	40
Client Metrics (%)									
Top 5 Clients	28.3	28	29.2	30.7	31.4	30.8	32.7	31.8	32.9
Top 10 Clients	39.5	39.3	40	41.5	41.5	40	42.2	42	43.2
Employee Metrics									
Technical People	21,263	21,738	22,224	21,866	21,675	22,407	23,072	23,787	24,608
Sales & BD	443	465	484	510	492	489	485	496	510
Others	1,136	1,133	1,142	1,143	1,070	1,046	1,037	1,057	1,106
Total	22,842	23,336	23,850	23,519	23,237	23,942	24,594	25,340	26,224
Effort Mix									
- Global Delivery Centers	12.70	13.80	14.80	15.20	15.80	15.10	14.80	14.50	14.10
- India	87.30	86.20	85.20	84.80	84.20	84.90	85.20	85.50	85.90
Attrition (%)	80.6	81.5	80	82.1	84.8	87.4	88.4	88.7	88.2
Linear Utilization %	13.5	11.9	11.5	11.9	12.0	12.6	12.9	13.9	13.8

Source: Company, MOFSL

Financials and valuations

Income Statement								(INR m)
Y/E March	2021	2022	2023	2024	2025	2026E	2027E	2028E
Sales	41,879	57,107	83,506	98,216	1,19,387	1,46,118	1,75,852	2,09,707
Change (%)	17.4	36.4	46.2	17.6	21.6	22.4	20.3	19.3
Cost of Goods Sold	27,650	37,895	55,315	65,231	78,740	94,517	1,14,137	1,36,310
Gross Profit	14,229	19,212	28,191	32,985	40,647	51,601	61,716	73,398
Selling Expenses	7,398	9,556	12,999	15,742	20,066	24,624	28,924	34,811
EBITDA	6,830	9,656	15,191	17,243	20,581	26,977	32,792	38,586
% of Net Sales	16.3	16.9	18.2	17.6	17.2	18.5	18.6	18.4
Depreciation	1,756	1,660	2,719	3,094	3,069	3,979	4,220	5,033
EBIT	5,075	7,996	12,472	14,149	17,512	22,998	28,571	33,553
% of Net Sales	12.1	14.0	14.9	14.4	14.7	15.7	16.2	16.0
Other Income	1,020	1,321	233	813	710	1,323	1,407	1,678
PBT	6,094	9,317	12,705	14,962	18,222	24,320	29,978	35,231
Tax	1,588	2,339	3,198	3,541	4,222	5,707	6,996	8,224
Rate (%)	26.1	25.1	25.2	23.7	23.2	23.5	23.3	23.3
Extraordinary Item	0	75	297	486	0	0	0	0
Adjusted PAT	4,507	6,904	9,211	10,935	14,001	18,613	22,982	27,007
Change (%)	32.4	53.2	33.4	18.7	28.0	32.9	23.5	17.5

Balance Sheet								(INR m)
Y/E March	2021	2022	2023	2024	2025	2026E	2027E	2028E
Share Capital	764	764	764	770	779	779	779	779
Other Reserves	27,192	32,918	38,887	48,807	62,411	73,579	87,369	1,03,572
Net Worth	27,957	33,682	39,651	49,577	63,191	74,359	88,148	1,04,352
Loans	44	4,889	4,947	99	-	-	-	-
Other liabilities	957	1,360	2,013	2,218	2,848	3,485	4,194	5,002
Capital Employed	28,958	39,931	46,610	51,894	66,038	77,844	92,342	1,09,354
Gross Block	17,788	27,391	33,914	32,079	36,920	42,420	47,920	53,420
Less : Depreciation	13,305	14,965	17,684	20,777	23,847	27,826	32,046	37,079
Net Block	3,254	4,276	7,058	6,727	8,150	9,670	10,950	11,417
CWIP	122	1,071	161	335	42	42	42	42
Intangibles	1,315	11,060	16,355	15,488	17,261	17,261	17,261	17,261
Investments	3,621	3,878	4,516	5,539	6,415	6,415	6,415	6,415
Deferred Tax Assets	1,038	1,123	1,129	1,360	2,024	1,461	1,759	2,097
Other	602	4,394	1,792	3,056	3,215	3,934	4,735	5,646
Current Assets	26,703	28,339	35,179	41,232	50,260	64,126	79,739	99,009
Debtors	5,709	9,484	15,705	16,761	18,478	20,817	25,053	29,876
Investments	13,765	10,514	6,242	6,330	6,899	9,399	11,899	14,399
Cash & BB	2,419	2,978	4,670	6,625	6,744	13,454	18,168	25,375
Loans & Advances	71	16	-	-	-	-	-	-
Other Current Assets	4,739	5,347	8,562	11,515	18,139	20,457	24,619	29,359
Current Liab. & Prov	7,697	14,210	19,581	21,842	21,328	25,066	28,558	32,534
Trade payables	2,733	4,299	5,689	8,139	8,886	11,609	13,972	16,662
Other Liabilities	2,486	5,961	9,243	10,372	8,413	8,526	8,652	8,796
Provisions	2,478	3,950	4,649	3,331	4,029	4,931	5,934	7,076
Net Current Assets	19,006	14,130	15,598	19,390	28,932	39,060	51,181	66,475
Application of Funds	28,958	39,931	46,610	51,894	66,038	77,844	92,343	1,09,354

Financials and valuations

Ratios

Y/E March	2021	2022	2023	2024	2025	2026E	2027E	2028E
EPS	29.5	45.7	62.5	75.1	90.2	119.1	147.0	172.7
Cash EPS	41.0	56.5	80.4	95.4	110.0	144.5	174.0	204.9
Book Value	182.9	220.4	260.7	325.9	411.9	478.5	566.7	670.9
DPS	10.0	15.5	25.0	26.0	35.0	47.6	58.8	69.1
Payout %	33.9	33.9	40.0	34.6	38.8	40.0	40.0	40.0
Valuation (x)								
P/E	181.0	116.9	85.4	71.1	59.2	44.8	36.3	30.9
Cash P/E	130.3	94.4	66.4	55.9	48.5	36.9	30.7	26.1
EV/EBITDA	117.1	83.6	53.1	46.3	39.1	29.9	24.4	20.5
EV/Sales	19.1	14.1	9.7	8.1	6.7	5.5	4.6	3.8
Price/Book Value	29.2	24.2	20.5	16.4	13.0	11.2	9.4	8.0
Dividend Yield (%)	0.2	0.3	0.5	0.5	0.7	0.9	1.1	1.3
Profitability Ratios (%)								
RoE	17.4	22.6	25.9	25.6	24.8	27.1	28.3	28.1
RoCE	14.1	17.4	21.6	21.9	22.8	24.5	25.7	25.5
Turnover Ratios								
Debtors (Days)	50	61	69	62	56	52	52	52
Asset Turnover (x)	13.9	15.2	14.7	14.2	16.1	16.4	17.1	18.8

Cash Flow Statement

(InR m)

Y/E March	2021	2022	2023	2024	2025	2026E	2027E	2028E
CF from Operations	5,781	8,857	13,935	14,265	17,803	22,592	27,202	32,040
Chg. in Working Capital	1,578	-407	-4,377	-2,052	-6,233	-437	-5,296	-6,030
Net Operating CF	7,359	8,450	9,558	12,213	11,569	22,155	21,906	26,010
Net Purchase of FA	-1,251	-3,808	-4,290	-2,710	-1,931	-5,500	-5,500	-5,500
Free Cash Flow	6,108	4,642	5,268	9,503	9,638	16,655	16,406	20,510
Net Purchase of Invest.	-4,166	-5,965	76	-1,985	-2,414	-2,500	-2,500	-2,500
Net Cash from Inv.	-5,417	-9,773	-4,213	-4,695	-4,344	-8,000	-8,000	-8,000
Issue of shares	0	0	0	1,608	0	0	0	0
Proceeds from LTB/STB	-3,044	3,810	-1,059	-3,461	-1,309	0	0	0
Dividend Payments	-1,070	-1,987	-2,981	-4,084	-4,973	-7,445	-9,193	-10,803
Net CF from Finan.	-4,114	1,823	-4,039	-5,937	-6,282	-7,445	-9,193	-10,803
Net Cash Flow	-2,171	499	1,305	1,581	943	6,710	4,714	7,207
Exchange difference	19	59	387	374	-824	0	0	0
Opening Cash Balance	4,572	2,420	2,979	4,671	6,626	6,745	13,455	18,169
Closing CashBalance	2,420	2,979	4,671	6,626	6,745	13,455	18,169	25,376

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered/qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:
financial interest in the subject company

- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal,

Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dp@motilaloswal.com.